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ImmunogenicityWe previously used human parainﬂuenza virus type 3 (HPIV3) as a vector to express the Ebola virus (EBOV)
GP glycoprotein. The resulting HPIV3/EboGP vaccine was immunogenic and protective against EBOV
challenge in a non-human primate model. However, it remained unclear whether the vaccine would be
effective in adults due to preexisting immunity to HPIV3. Here, the immunogenicity of HPIV3/EboGP was
compared in HPIV3-naive and HPIV3-immune Rhesus monkeys. After a single dose of HPIV3/EboGP, the
titers of EBOV-speciﬁc serum ELISA or neutralization antibodies were substantially less in HPIV3-immune
animals compared to HPIV3-naive animals. However, after two doses, which were previously determined to
be required for complete protection against EBOV challenge, the antibody titers were indistinguishable
between the two groups. The vaccine virus appeared to replicate, at a reduced level, in the respiratory tract
despite the preexisting immunity. This may reﬂect the known ability of HPIV3 to re-infect and may also
reﬂect the presence of EBOV GP in the vector virion, which confers resistance to neutralization in vitro by
HPIV3-speciﬁc antibodies. These data suggest that HPIV3/EboGP will be immunogenic in adults as well as
children., NIH, 50 South Drive, Room
8312.
eyev).
Inc.Published by Elsevier Inc.Introduction
Ebola virus (EBOV), along with Marburg virus, belongs to the
family Filoviridae and causes periodic outbreaks of a severe
hemorrhagic fever with a high mortality in Central Africa. The virus
is transmitted by direct contact with an infected person, their
biological ﬂuids, or cadavers. The virus is highly contagious, and
transmission occurs through mucosal surfaces and/or breaks in the
skin (reviewed in Sanchez, Geisbert, and Feldmann, 2007). Aerosol-
ized EBOV was demonstrated to cause lethal infections in monkeys
(Johnson et al., 1995), and, therefore, the virus is considered a
potential agent for biological warfare and bioterrorism. Early attempts
to develop a vaccine against EBOV based on inactivated viral particles,
puriﬁed antigens, and other approaches sometimes were protective in
rodents but were not protective or poorly protective in non-human
primates (reviewed in Kuhn, 2008). More recently, vectored vaccines
and virus-like particles proved to be protective in non-human primate
models (Jones et al., 2005; Sullivan et al., 2000, reviewed in Bukreyev
and Collins, 2010).
Human parainﬂuenza virus type 3 (HPIV3) is a common pediatric
respiratory virus. HPIV3 is a member of family Paramyxoviridae and isan enveloped virus with a single negative-sense strand of genomic
RNA of 15,462 nucleotides. Live-attenuated pediatric vaccines against
HPIV3 are actively being developed that include the use of HPIV3 as a
vector to express protective antigens of other pediatric viruses
(Durbin et al., 2000; Karron et al., 2003). Thus, there is substantial
experience with the natural history of HPIV3 in humans and with the
administration of HPIV3 derivatives in clinical trials. We were
interested in evaluating HPIV3 as a potential vector against EBOV
and other emerging pathogens because it induces strong mucosal
responses in addition to strong systemic responses and thus should be
particularly effective in protecting mucosal surfaces.
We modiﬁed HPIV3 to express the EBOV glycoprotein (GP), the
only EBOV envelope surface protein, from an additional gene inserted
between the HPIV3 P andM genes (Bukreyev et al., 2006). Respiratory
tract immunization of guinea pigs with HPIV3/EboGP did not cause
any disease or signiﬁcant lung pathology, and there was no evidence
of viral spread beyond the respiratory tract and no evidence of
pathologic changes in internal organs (Bukreyev et al., 2006, 2009;
Yang et al., 2008). Similarly, HPIV3/EboGP (as well as its wild-type
HPIV3 parent) was asymptomatic in non-human primates (Bukreyev
et al., 2007). The lack of virulence of HPIV3 and its HPIV3/EboGP
derivative in non-human experimental animals presumably reﬂects a
host range restriction on this human virus. Thus, evaluation of vectors
based on wild-type HPIV3 in non-human experimental animals
provides a model for attenuated derivatives in humans. There was
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replication or tropism in vivo. Indeed, the titers of HPIV3/EboGP in
the respiratory tract of guinea pigs and monkeys were similar to or
lower than that of the empty HPIV3 vector (Bukreyev et al., 2007,
2009; Yang et al., 2008). More importantly, the vaccine was found to
be protective against intraperitoneal challenge with a highly lethal
dose of EBOV both in guinea pig and non-human primate models of
infection (Bukreyev et al., 2006, 2007). However, essentially all adult
humans have preexisting immunity to HPIV3 from natural exposure.
This immunity would be expected to restrict replication of the HPIV3
vector andmight drastically reduce the immunogenicity of the foreign
insert antigen. Therefore, it was unclear whether this vector would be
effective in HPIV3-immune humans. Indeed, preexisting immunity to
other viral vectors such as ones based on vaccinia virus or adenovirus
type 5 greatly reduced the immune responses to expressed foreign
antigens (see Discussion). Surprisingly, in guinea pigs that had
previously been infected with HPIV3, immunization with a single dose
of HPIV3/EboGP induced titers of EBOV-speciﬁc serum antibodies that
nearly equaled those detected in HPIV3- naive animals (Yang et al.,
2008). However, since evaluation of vaccines in rodent models can
produce overly optimistic results, testing in non-human primates is an
important step in evaluating immunogenicity and efﬁcacy. This is
particularly true for ﬁlovirus vaccines (Geisbert et al., 2002).
In this study, we evaluated the immunogenicity of HPIV3/EboGP in
HPIV3-immune monkeys. We found that preexisting HPIV3-speciﬁc
immunity reduced but did not prevent replication of the vaccine in the
respiratory tract and that the level of EBOV-speciﬁc antibodieswas equal
to that in HPIV3-naive primates following two doses of the vaccine.
Results
Two doses of HPIV3/EboGP are equally immunogenic in HPIV3-naive
and HPIV3-immune monkeys
To compare the immunogenicity of HPIV3/EboGP in HPIV3-immune
and non-immune animals, we infected four HPIV3-seronegative
monkeys with two doses of HPIV3, 4 weeks apart, by the combined
intranasal (IN) and intratracheal (IT) route. Eachdose contained 106 50%
tissue culture infectious doses (TCID50) per site (Fig. 1). The ﬁrst dose
induced HPIV3-speciﬁc hemagglutination inhibition (HAI) serum anti-
bodies with a geometric mean titer of 1:3400, which was not increased
after the second dose (Fig. 2A). Essentially all humans are infected with
HPIV3 during infancy and early childhood and may be re-infected
thereafter. Thus, the typical adultwouldhavebeen infectedonceormore
with HPIV3 (hence the animals received two doses) but, in most cases,
would not have been infected recently. A substantial component of theFig. 1. Design of the study. The arrows above the horizontal lines indicate virus inoculations,
blood samplings are counted after the ﬁrst dose of HPIV3 (left side) or the ﬁrst dose of HPIV3
8, and 10.protective cellular immunity induced by HPIV3 infection is lost within a
few months (Tao et al., 2000) and, thus, would have been lost in the
typical adult. In order tomodel this situation, the animalswere rested for
11 months after the second dose of HPIV3. We detected no reduction in
the level of HPIV3-speciﬁc serum antibodies over that time (Fig. 2A).
Thereafter, two additional HPIV3-seronegative monkeys were added to
the study as HPIV3- naive controls, and all six animals were immunized
with two doses of HPIV3/EboGP, 4weeks apart, by the combined IN and
IT routewith 107 plaque-forming units (PFU) per site (Fig. 1).We used a
10-fold higher dose of HPIV3/EboGP than HPIV3 because HPIV3/EboGP
appeared to be attenuated in vivo compared to HPIV3. For example,
HPIV3/EboGP replicated up to 100-fold less efﬁciently in the lungs of
guinea pigs in previous studies (Yang et al., 2008, Bukreyev et al., 2009).
This difference was not apparent in an earlier study that monitored
shedding from rhesus monkeys (Bukreyev et al., 2007). However, in
rhesusmonkeys, a dose of 106 TCID50 per site of HPIV3 induced a serum
antibody response that was not augmented by a second dose and thus
appeared to bemaximal (asnoted above),whereas in a previous study in
rhesusmonkeys, a dose of 107 TCID50 per site of HPIV3/EboGP induced a
higher serum antibody response to the vector and the insert than did a
dose of 2×106 TCID50 per site (Bukreyev et al., 2007), suggesting that the
higher dose would be necessary to approach a maximal response.
We previously demonstrated that two doses of HPIV3/EboGP are
required for a uniform protection against EBOV challenge in a non-
human primate model (Bukreyev et al., 2007). Consistent with that
study, administration of the ﬁrst dose of HPIV3/EboGP to HPIV3-naive
animals in the present study induced substantial titers of serum
EBOV-speciﬁc IgG and IgA, as quantiﬁed by an enzyme-linked
immunosorbent assay (ELISA) (Figs. 2B, C). The second dose of
HPIV3/EboGP was followed by a modest increase in the antibody
titers, although by day 42 after the second dose, the titer of serum IgG,
but not IgA, diminished to that induced by the ﬁrst dose (Figs. 2B, C).
Titers of EBOV-neutralizing antibodies were assayed by the ability to
neutralize the virus VSVΔG/ZEBOVGP (Garbutt et al., 2004), which is
a recombinant version of vesicular stomatitis virus (VSV) in which the
VSV envelope glycoprotein G was deleted and replaced by EBOV GP as
the sole viral surface protein. This chimeric virus depends on EBOV GP
for cell attachment and entry and, therefore, is a suitable alternative in
neutralization assays to the authentic EBOV Zaire virus, which
requires a biosafety level (BSL)-4 facility. In the HPIV3-naive animals
immunized with HPIV3/EboGP, we detected a 1:13 geometric mean
titer of EBOV-neutralizing antibodies after the ﬁrst dose, which
increased after the second dose to 1:54 (Fig. 2D).
In the HPIV3-immune monkeys, the ﬁrst dose of HIPV3/EboGP
induced titers of EBOV-speciﬁc serum IgG and IgA antibodies that were
signiﬁcantly reduced compared to theHPIV3-naivemonkeys (Figs. 2B, C).and those below indicate days of blood sample collection. Days of virus inoculations and
/EboGP (right side). The horizontal bars indicate collections of NS and TL on days 2, 4, 6,
Fig. 2. Immunogenicity of HPIV3/EboGP in HPIV3-immune (grey bars) and HPIV3- naive (white bars) monkeys. The days onwhich HPIV3 (A, left side) or HPIV3/EboGP (A, right side,
B, C, D) were administered are indicated with arrows. The days after dose 1 of HPIV3 (A, left side) or HPIV3/EboGP (A, right side, B, C, D) are indicated. All titers are expressed as
reciprocal mean log2 values. (A) HPIV3-speciﬁc serum antibody (Ab) levels determined by HAI. Left side, antibody titers (HPIV3-immune group only) after infection with HPIV3,
mean values±SE for the four animals in the group; right side, antibody titers after infection with HPIV3/EboGP of the two HPIV3-naive animals, mean values, and the four HPIV3-
immune animals, mean values±SE. (B, C) EBOV-speciﬁc serum IgG (B) and IgA (C) quantitated by ELISA using inactivated puriﬁed EBOV as antigen. Mean titers of the two HPIV3-
naive and mean titers±SE of the four HPIV3-immune animals are shown. However, for days 28 and 56 (bars indicated with X), the data for the two HPIV3-naive animals were
augmented by analysis, in parallel, of samples from three additional animals from a previous study in which the monkeys were immunized exactly as in the present study (Bukreyev
et al., 2007); thus, for these time points, the HPIV3- naive group is represented by mean values±SE of a total of ﬁve samples. (D) EBOV-neutralizing (neut) serum antibodies
analyzed using VSVΔG/ZEBOVGP, which is a recombinant VSV bearing an envelope in which EBOV GP is the sole viral surface antigen. Mean titers of the two HPIV3-naive and mean
titers±SE of the four HPIV3-immune animals are shown. Comparisons of IgG and IgA responses (panels B and C, respectively) between the HPIV3-naive and the HPIV3-immune
monkeys on days 28 and 56 are indicated by horizontal lines; statistically signiﬁcant differences (pb0.05) are indicated by asterisks. For the samples in which antibodies were not
detected, the value 1 log2 was assigned for calculation of the mean (panels A, C, D).
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HPIV3-immune animals were essentially equal to those in the HIPV3-
naive animals. The EBOV-neutralizing antibodies were not detectable
after the ﬁrst dose; however, after the second dose, the geometric mean
titer 1:85 was detected that exceeded the titer in the HPIV3-naive group
(Fig. 2D). These data indicate that two doses of HPIV3/EboGP were as
immunogenic in HPIV3-immune monkeys as in HPIV3-naive monkeys.
We also performed the neutralization assay of sera from the two HPIV3-
naive and two HPIV3-immune animals in the absence of guinea pig
complement. Interestingly, little or no EBOV-neutralizing activity was
detectable in most of the samples. In particular, low titers, 1:9 and 1:6,
were detected in sera from one HPIV3-naive and one HPIV3-immune
monkey, respectively, after the second but not the ﬁrst dose (data not
shown). These data suggest that at least in the case of vaccination with
HPIV3/EboGP, the complement system is an important component of
EBOV neutralization by antibodies.
Preexisting vector-speciﬁc immunity does not prevent replication of the
vaccine in the respiratory tract
In the experiment shown in Fig. 1, nasal swabs (NS) and tracheal
lavages (TL) were collected after immunization of HPIV3-naive and
-immune animals with HPIV3/EboGP (Fig. 1) in order to measure
vaccine virus shedding. The samples were assayed by plaque titrationand the titers were expressed as PFU per milliliter of NS or TL ﬂuids.
Relatively high titers of viable vaccine virus were detected in NS and
TL specimens collected from HPIV3-naive monkeys on days 2, 4, 6, but
not days 8 and 10, after the ﬁrst dose of the vaccine (Fig. 3A). In
contrast, infectious virus was not detected in NS and TL specimens
collected from the HPIV3-immune monkeys. Furthermore, infectious
virus was not detected in NS and TL specimens from either group
collected after the second dose of the vaccine. These data suggested
that the immunity induced by HPIV3 or HPIV3/EboGP strongly
restricted replication of a subsequent dose of HPIV3/EboGP. However,
we previously showed that UV-inactivated HPIV3/EboGP induced
only a low level of EBOV-speciﬁc serum antibody in guinea pig model,
indicating that a signiﬁcant immune response to HPIV3/EboGP
depends on its replication (Yang et al., 2008). As noted later in this
report, UV-inactivated HPIV3/EboGP also did not induce detectable
IgG or IgA ELISA serum antibodies in HPIV3-naive Rhesus monkeys,
showing that replication is necessary for signiﬁcant immunogenicity
in non-human primates. Thus, the increase in the immune response to
each dose of HPIV3/EboGP in HPIV3-immune monkeys in the present
study raised the possibility that replication of HPIV3/EboGP was
occurring following each dose even though infectious virus was not
detectable in any of the NS and TL specimens by plaque assay.
We therefore used quantitative reverse transcription–polymerase
chain reaction (RT-PCR) to quantify HPIV3 RNA present in NS and TL
Fig. 3. Shedding of the HPIV3/EboGP vaccine virus in HPIV3-naive and HPIV3-immune monkeys. NS and TL samples were collected on the indicated days and analyzed later in
parallel by plaque titration or quantitative RT-PCR. Each bar represents an individual monkey. (A) Plaque titration of NS and TL specimens after dose 1. The limit of detection was 5
PFU/ml; for the samples in which virus was not detected, values twofold below the limit of detection were assigned. Virus was not detected in any animal after dose 2 (see Results).
(B, C) Quantitative RT-PCR analysis of NS and TL specimens after dose 1 (B) and dose 2 (C). The quantitative RT-PCR results are expressed as PFU per milliliter based on comparison
with a standard curve constructed by quantitative RT-PCR analysis of RNA samples from serial dilutions of a preparation of HPIV3/EboGP with a known PFU per milliliter
concentration. The non-speciﬁc background signal, determined using NS and TL from monkeys from an unpublished study that were inoculated with a Newcastle disease virus
vector, was 2.8–2.9 and 3.0–3.1 log10 PFU equivalents per milliliter in NS and TL, respectively. The assay was repeated four times.
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control, analysis of specimens from two monkeys infected with an
unrelated viral vector (i.e., samples collected on day 4 after IN and IT
inoculation of Rhesus monkeys with 107 PFU of a recombinant
Newcastle disease virus expressing EBOV GP [J.M.D., P.L.C., A.B.,
unpublished data]) indicated that the non-speciﬁc background was
2.8–2.9 and 3.0–3.1 log10 PFU equivalents per milliliter in NS and TL,
respectively. After the ﬁrst dose of HPIV3/EboGP in HPIV3-naive
animals, the level of viral RNA signiﬁcantly exceeded this non-speciﬁc
control in both the NS and TL for most of the time points. Importantly,
substantial concentrations of the viral RNA also were detected in many
of the NS and TL specimens from HPIV3-immune monkeys, mostly on
days 2 and 4 (Fig. 3B). Interestingly, after the second dose of HPIV3/
EboGP, high concentrations of HPIV3 RNA were detected in NS
specimens of both HPIV3-naive and HPIV3-immune animals, whereas
little ornoHPIV3RNAwasdetected inTL specimens(Fig. 3C). Thesedata
indicate that RNA from the HPIV3 vector is present in the respiratory
tract of both HPIV3-naive and HPIV3-immune monkeys not only after
the ﬁrst dose of HPIV3/EboGP but also after the second dose.
Replication of HPIV3/EboGP is necessary for RNA detection in NS and TL
speciments and for immunogenicity
We next asked whether the vector RNA detected in the respiratory
tract secretions represents progeny virus produced by viral replicationin vivo or represents the initial viral inoculum. To distinguish between
these two possibilities, we performed a separate experiment with four
seronegative Rhesusmonkeys in which twomonkeys were inoculated
with live HPIV3/EboGP and two with UV-inactivated HPIV3/EboGP.
The animals received either virus by the combined IN and IT route at
107 PFU (or its equivalent) per site. On days 2, 4, 6, 8, and 10, NS and TL
were collected and analyzed for the presence of viable virus by plaque
titration (Fig. 4A) or for the presence of HPIV3 RNA by quantitative
RT-PCR (Fig. 4B). As expected, plaque assay of the NS and TL
specimens collected from the two monkeys that received live
HPIV3/EboGP virus revealed viral titers comparable to those observed
in the ﬁrst monkey experiment (as was shown in Fig. 3A), whereas no
infectious virus was detected in specimens from the two animals that
received UV-inactivated HPIV3/EboGP (Fig. 4A). Furthermore, quan-
titative RT-PCR demonstrated the presence of HPIV3 RNA in the NS
and TL samples of the monkeys inoculated with live HPIV3/EboGP, at
concentrations comparable to those observed in the ﬁrst monkey
experiment (as was shown in Fig. 3B), but not in the samples collected
from the monkeys inoculated with UV-inactivated HPIV3/EboGP
(Fig. 4B).
As a control, we compared the sensitivity of quantitative RT-PCR
for live versus UV-inactivated HPIV3/EboGP. We found that UV
inactivation reduced the sensitivity of the assay by 1.7 log10 (not
shown). This loss in sensitivity presumably is due to damage to most
of the RNA template by the introduction of uracil dimers, since even
Fig. 4. Analysis of NS and TL specimens collected after inoculation of HPIV3-naive monkeys with HPIV3/EboGP or UV-inactivated HPIV3/EboGP for the presence of infectious virus by
plaque titration (A) or the presence of HPIV3/EboGP RNA by quantitative RT-PCR (B) calculated as in the assay shown in Fig. 3 (B, C). Each bar represents an individual monkey. In
part A, the limit of detection was 5 PFU/ml; for the samples in which no virus was detected, values twofold below the limit of detection were assigned. In part B, the value 2.9 log10,
which is twofold below the limit of detection and represents the titer detected in the last (least concentrated) dilution of the HPIV3/EboGP standard curve, was assigned to the
samples in which RNA was not detected. The assay was repeated two times.
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the virus used here, a large fraction of the RNA molecules received
multiple hits. In any event, this value is well below the difference
between the levels of RNA in some of the NS and TL samples positive
for the viral RNA and the limit of detection. For example, the
difference between the levels of RNA detected in some monkeys on
days 4 and 6 and the limit of detection (3.2 log10) was 2.7 and 3.1 log10
for NS and TL, respectively (Fig. 4B).This indicates that the HPIV3
vector RNA that was detected in NS and TL specimens following the
ﬁrst and second inoculation with HPIV3/EboGP was due to replicated
virus rather than residual inoculum.
Finally, we collected serum samples 28 and 56 days following
immunization with UV-inactivated versus infectious HPIV3/EboGP.
The UV-inactivated virus did not induce detectable EBOV-speciﬁc
ELISA IgG or IgA serum antibodies, whereas strong responses were
observed in animals that received infectious HPIV3/EboGP, similar to
results described above and in previous work (not shown). This
conﬁrmed that replication of HPIV3/EboGP was necessary for
signiﬁcant EBOV-speciﬁc antibody responses in primates, as had
previously been observed in guinea pigs (Yang et al., 2008).
NS and TL specimens from HPIV3-immune animals neutralize the
infectivity of HPIV3 and HPIV3/EboGP in vitro
We next attempted to determine why the HPIV3/EboGP vaccine
virus was detectable in respiratory secretions by quantitative RT-PCR,
but not by plaque titration. One possibility was that HPIV3/EboGP
indeed was secreted from the respiratory tract epithelial cells but was
neutralized by HPIV3-speciﬁc antibodies present in the respiratory
tract either immediately upon its release, or in vitro during analysis ofthe specimens by plaque assay. To investigate this possibility, we
performed spiking experiments in vitro in which replicate aliquots of
150 μl containing 300 PFU of either HPIV3 or HPIV3/EboGP were
mixed with 150 μl of NS or TL specimen from the HPIV3-naive or
-immune animals indicated in Fig. 3. As a control, we tested one set of
specimens (number 2 in Fig. 5) collected on day 4 after infection with
Newcastle disease virus (from an unpublished study), in which no
HPIV3-speciﬁc neutralizing antibodies would be expected to be
present. We also assayed two sets of specimens (numbers 3 and 4)
collected from HPIV3-naive monkeys on day 2 after infection with the
ﬁrst dose of HPIV3/EboGP. Day 2 is an early time point when any
HPIV3-speciﬁc neutralizing activity present in the serum or in the
respiratory tract secretions would be due to antibodies present before
infection with HPIV3/EboGP (i.e., present from the original HPIV3
infections 11 months earlier). Other samples included four sets of
specimens (numbers 5–8) collected from HPIV3-immune animals on
day 2 after the ﬁrst dose of HPIV3/EboGP. All of the NS and TL
specimens were UV-irradiated to destroy any infectious HPIV3/
EboGP, which was conﬁrmed by plaque assay. The mixtures were
incubated for 1 h at 37 °C, and the residual titers of spiked virus were
quantiﬁed by plaque titration (Fig. 5). We found no consistent
reduction in viral titers by NS specimens collected from the HPIV3-
naive monkeys. In contrast, the number of PFU of HPIV3 was reduced
by all four NS samples from the HPIV3-immune monkeys by 4.5-fold
to at least 560-fold (below the limit of detection for NS number 5) and
that of HPIV3/EboGP was reduced by two out of four NS samples by
74- and 4.3-fold. TL specimens collected from the HPIV3-naive
monkeys only marginally reduced titers of both viruses; however,
the reduction was much greater in the case of TL specimens collected
from the HPIV3-immune animals. In particular, the titers of HPIV3
Fig. 5. Evaluation of the ability of NS (A) and TL (B) ﬂuids collected from HPIV3-naive
and HPIV3-immune monkeys to neutralize HPIV3 wild-type virus (black bars) or the
HPIV3/EboGP vaccine virus (striped bars) added in vitro at 103 PFU/ml. The following
NS and TL specimens or control were combined with HPIV3 or HPIV3/EboGP in the
neutralization test: 1, control in which phosphate-buffered saline was added to the
HPIV3 or HPIV3/EboGP preparations; 2, NS and TL specimens collected on day 4 after
infection of a rhesus monkey with 2×107 PFU of Newcastle disease virus in a previous
unpublished study; 3 and 4, NS and TL specimens collected from two different HPIV3-
naive monkeys collected on day 2 after the ﬁrst dose of HPIV3/EboGP; 5–8, NS or TL
samples collected from four different HPIV3-immune monkeys collected on day 2 after
the ﬁrst dose of HPIV3/EboGP. All specimens were UV-irradiated before use in order to
inactivate shed virus. The added test virus was completely neutralized in the case of
HPIV3, NS number 5 (indicated with a single asterisk) and for both HPIV3 and HPIV3/
EboGP in the case of TL number 6 (two asterisks). The limit of detection was 5 PFU/ml.
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for TL number 6), and those of HPIV3/EboGP were slightly reduced
(by 1.6- to 2.1-fold), or reduced to undetectable level (i.e., by at least
1040-fold) by TL number 6. The seemingly greater resistance of
HPIV3/EboGP to neutralization by HPIV3-immune NS and TL speci-
mens would be consistent with our previous ﬁnding that HPIV3/
EboGP is less susceptible than the HPIV3 empty vector to neutrali-
zation by HPIV3-speciﬁc antibodies due to the presence of functional
EBOV GP incorporated into the vector particle (Bukreyev et al., 2006),
although the number of monkeys examined here was insufﬁcient to
unequivocally demonstrate this effect. We also tested the respiratory
tract secretions for the ability to neutralize added human respiratory
syncytial virus (RSV), a serologically unrelated paramyxovirus, and
found a lack of any signiﬁcant neutralizing activity (not shown). This
supports the idea that the neutralizing activity against HPIV3 andHPIV3/EboGP was speciﬁc. These data indicate that HPIV3-speciﬁc
antibodies present in NS and TL specimens can neutralize HPIV3 and
HPIV3/EboGP, and thus virus that is shed and present in respiratory
secretions from HPIV3-immune (and HPIV3/EboGP-immune)
monkeys might be missed by plaque titration.
Discussion
This report demonstrated that an HPIV3-vectored vaccine against
EBOV replicates and is immunogenic in HPIV3-immune non-human
primates. Indeed, the levels of EBOV-speciﬁc serum antibodies
detected by ELISA, an important correlate of protection for EBOV
(reviewed in Sullivan et al., 2009), or by a neutralization assay
following two doses of the vaccine were indistinguishable from those
of HPIV3-naive animals. These results contrast with similar studies
involving vaccinations with two or even three doses of other vectors
based on common human viral pathogens such as vaccinia virus and
adenovirus type 5 administered by intramuscular route. For example,
following immunization of Rhesus monkeys with a vaccinia virus-
vectored vaccine expressing the simian immunodeﬁciency virus
group antigen (gag) protein, gag-speciﬁc cytotoxic T cell (CTL)
responses were severely attenuated by preexisting immunity to the
vaccinia virus vector (Sharpe et al., 2001). In clinical trials, a vaccinia
virus-vectored vaccine against Japanese encephalitis virus induced
neutralizing serum antibody responses only in vaccinees that did not
have prior immunity to vaccinia virus (Kanesa-Thasan et al., 2000).
Similarly, pre-exposure of mice and Rhesus monkeys to human
adenovirus type 5, the serotype most common in the human
population, severely attenuated the immune response to the gag
protein of human immunodeﬁciency virus type I or simian immuno-
deﬁciency virus expressed by a vaccine based on this vector (Barouch
et al., 2004; Casimiro et al., 2003; Lemckert et al., 2005; McCoy et al.,
2007). Similarly, pre-exposure of mice to human adenovirus type 5
greatly reduced the EBOV-speciﬁc antibody and cell-mediated
responses to an adenovirus 5-based vector expressing the EBOV GP
(Yang et al., 2003).
UV-inactivation of the HPIV3/EboGP vaccine abrogated its immu-
nogenicity in guinea pigs (Yang et al., 2008) and non-human primates
(present study), indicating that its immunogenicity depends on
replication. Therefore, the observation that HPIV3/EboGP was
immunogenic in HPIV3-immune animals following each of the two
doses suggested that at least some replication of HPIV3/EboGP
occurred following each dose despite preexisting immunity. Indeed,
quantitative RT-PCR demonstrated the presence of HPIV3-speciﬁc
RNA in NS and TL specimens from both HPIV3-naive and HPIV3-
immune animals following each dose of HPIV3/EboGP. These data are
consistent with a recently published study (Boukhvalova et al., 2007)
in cotton rats with RSV, which, like HPIV3, is a respiratory
paramyxovirus with the ability to cause re-infections (reviewed in
Collins and Crowe, 2007). This study demonstrated that, in cotton rats
previously infectedwith RSV, a second RSV infection does not result in
any detectable PFU in the lungs, as evaluated by plaque assay of
homogenates of the harvested lungs. However, quantitative RT-PCR
analysis of the lung tissues demonstrated substantial titers of viral
RNA, which at early time points were comparable to those during the
primary infection. The authors interpreted these data to suggest that
preexisting RSV immunity led to “abortive replication” in the
respiratory tract tissues of infected animals. However, they did not
address the alternative possibility that the second infectionmight lead
to the production of progeny virus that was subsequently neutralized
by endogenous antibodies, either in vivo or in the context of their in
vitro plaque assay. Our study, which analyzed respiratory secretions
rather than lung tissue, showed that the NS and TL specimens from
HPIV3-immune animals, but not from HPIV3-naive animals, neutral-
ized added HPIV3 or HPIV3/EboGP in vitro, indicating the presence of
neutralizing antibodies. The presence of virus-speciﬁc antibodies in
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known (Brown et al., 1985; Burlington et al., 1983). This suggests that
progeny HPIV3/EboGP was produced and shed into the respiratory
tract but was neutralized by antibodies present in the respiratory
secretions. This is offeredwith the caveat that we did not demonstrate
that the viral RNA present in the NS and TL samples was in the form of
virus particles.
How was HPIV3/EboGP able to replicate in the respiratory tract in
the presence of preexisting HPIV3-speciﬁc immunity? One explana-
tion may lie in the ability of respiratory paramyxoviruses, including
HPIV3 and RSV, to re-infect throughout life despite the presence of
immunity due to prior infection. This appears to be due to several
factors. For example, the rises in virus-speciﬁc secretory IgA titer in
the respiratory tract that occur following infection can diminish
within months. Virus-speciﬁc serum antibody responses are longer
lived, but these antibodies gain access to the respiratory lumen
inefﬁciently, limiting their ability to restrict virus replication in
luminal epithelial cells. Virus-speciﬁc CTL induced by infection
diminish within a few months, and secondary responses may not be
fast enough to prevent extensive virus replication. Furthermore, a
number of laboratories have presented evidence that virus-speciﬁc
CTL are functionally down-regulated in the respiratory tract, presum-
ably as a means of limiting their ability to damage tissue (Claassen et
al., 2005; DiNapoli et al., 2008; Fulton et al., 2008; Gray et al., 2005;
Vallbracht et al., 2006). Taken together, these factors limit the ability
of preexisting immunity to restrict re-infection by respiratory viruses
(reviewed in Collins and Crowe, 2007; Karron and Collins, 2007). In
agreement with this, the above-noted suppressive effect of the
preexisting antibodies on human adenovirus-5-vectored vaccine
against EBOV delivered intramuscularly was bypassed by intranasal
delivery of the vaccine, at least in mice (Croyle et al., 2008); no such
results have been reported for non-human primates so far. Another
explanation may be related to a relatively high, 2×107 PFU, dose of
the vaccine virus, which might not be fully neutralized by the amount
of HPIV3-speciﬁc antibodies available locally in the respiratory tract.
The third explanationmay lie in the presence of functional EBOV GP in
the HPIV3/EboGP envelope. As already noted, EBOV GP is incorpo-
rated into the HPIV3/EboGP viral particles, conferring the ability to
evade efﬁcient neutralization by HPIV3-speciﬁc antibodies in vitro
(Bukreyev et al., 2006). Thus, EBOV GP may be mediating virus
attachment and entry in the respiratory tract of both naive and HPIV3-
immune non-human primates, thereby further circumventing the
neutralizing antibody response against HPIV3.
How can this limited level of replication induce an immune
response in HPIV3-immune animals that attain the level observed in
HPIV3-naive animals? Several studies in which mice were inoculated
with respiratory viruses by the IN route demonstrated that migration
of activated dendritic cells from the lungs into the draining lymph
nodes occurs within hours post-infection. In particular, after infection
of mice with Sendai virus, a murine paramyxovirus closely related to
HPIV1 and HPIV3, lung dendritic cells were detected in peribronchial
lymph nodes at 6–12 h post-infection (Grayson et al., 2007). RSV
infection of mice resulted in the accumulation of lung dendritic cells in
mediastinal lymph nodes at 12 h, the earliest time point tested, and
reached a peak 18 h post-infection (Lukens et al., 2009). After infection
of mice with inﬂuenza A virus, accumulation of lung dendritic cells in
peribronchial lymph nodes was detected as early as 6 h and reached a
maximum18 h post-infection. Moreover, at 48 h following infection in
mice, pulmonary dendritic cells became refractory to activation by a
secondary infection with an unrelated strain of the virus (Legge and
Braciale, 2003). These data suggest that the activation of respiratory
dendritic cells resulting in migration to secondary lymphoid tissue is
primarily an early event during virus infection. It appears to be
mediated mostly by early viral progeny produced after a limited
number of infection cycles rather than by virus produced later at the
peak of viral replication. In this regard, it is noteworthy that thedetection of HPIV3 RNA following inoculation of HPIV3-immune
animals with HPIV3/EboGPwas greatest on day 2 post-immunization,
with detection subsequently declining with increasing time. At this
early time, the amount of vector RNA was similar between HPIV3-
immune and -naive animals in the NS specimens and was somewhat
reduced in the TL specimens fromHPIV3-immune animals. Thus, three
features of the HPIV3/EboGP vaccine may contribute to its immuno-
genicity in vector-immune animals: ﬁrst, the inefﬁciency of preexist-
ing immunity in restricting HPIV3 replication; second, the presence of
a functional EBOV GP; and third, the disproportionate role of early
activation of respiratory antigen-presenting cells in the adaptive
response.
It should be noted that we did not measure EBOV-speciﬁc cell-
mediated responses in this particular study. Cell-mediated responses
have been described to be required for protection of monkeys against
EBOV challenge after vaccination with adenovirus-type 5-vectored
vaccine (Sullivan et al., 2009), although the details of this study have
not yet been published. However, we previously showed that
administration of HPIV3/EboGP to the respiratory tract of non-
human primates results in only a low, sporadic cellular response
detected in the peripheral blood, whichmight be a consequence of the
cellular response accumulating at the respiratory tract site of infection
(reviewed in Bukreyev and Collins, 2010). Thus, we did not monitor
cell-mediated responses in the present study. In contrast, the serum
antibody response is robust, whether measured by ELISA or
neutralizing assays, and likely plays an important role in protection
(reviewed in Bukreyev and Collins, 2010). Furthermore, we did not
test the protective efﬁcacy of the vaccine in the HPIV3-immune
animals in the present study due to a current unavailability of a BSL-4
facility. This important experiment will be performed in follow-up
studies, although we note that the levels of serum ELISA and
neutralizing antibodies observed in the present study would be
consistent with a high level of protection. It should also be noted that
the combined IN and IT route of inoculation was used in our non-
human primate studies in an effort to achieve uniform infection of the
animals, which is essential in studies involving a small number of
animals. While IT delivery would not be feasible in humans, delivery
by the IN route alone should be sufﬁcient since humans are the natural
host for the HPIV3 vector and are more permissive than non-human
primates. Alternatively, the vaccine can be delivered in the form of
aerosol using a nebulizer. This mode of delivery was previously used
to successfully deliver measles virus vaccine to four million children
(Fernandez Bracho and Roldan Fernandez, 1990; Fernandez-de Castro
et al., 1997), and a similar apparatus was recently used for evaluating
a vectored respiratory tract vaccine against H5N1 highly pathogenic
avian inﬂuenza virus in monkeys (Dinapoli et al., 2010).
The present data suggest that the effectiveness of an HPIV3-based
vector may not be strongly suppressed by preexisting immunity to the
vector. We also have developed an alternative strategy to circumvent
the moderate suppression of immunogenicity by preexisting immunity
to the HPIV3 vector. Speciﬁcally, we developed an HPIV3-based
construct, HPIV3/ΔF-HN/EboGP, in which the HPIV3 F and HN genes,
which encode the neutralization and major protective antigens of
HPIV3, were replaced by EBOV GP (Bukreyev et al., 2009). TheHPIV3/
ΔF-HN/EboGP virus was insensitive to HPIV3-neutralizing antibodies in
vitro, was highly attenuated in guinea pigs, was strongly immunogenic
in HPV3-immune and -naive animals, and was completely protective
against EBOV challenge. Either type of vaccine virus is a candidate for
clinical trials in adults. Both the HPIV3/EboGP and theHPIV3/ΔF-HN/
EboGP vaccines have several important advantages. First, they do not
replicate beyond the respiratory tract and therefore are very safe.
Second, they induce not only systemic but also local immune responses
in the respiratory tract, a possible port of entry of EBOV. Third, they are
needle-free, increasing the safety and ease of administrationby IN route,
which is likely tobeas effective as the combined INand IT route tested in
the present study due to the full permissiveness of human to the HPIV3
297A.A. Bukreyev et al. / Virology 399 (2010) 290–298vector. Fourth, their production would be relatively straightforward,
since both of the vaccines represent replication-competent viruses
capable of effective replication in cell lines approved for vaccine
production, such as Vero, and do not require enhanced safety under
BSL-3 or BSL-4 containment.
Materials and methods
Immunization of rhesus monkeys
Rhesusmonkeys (Macacamulatta)were fromMorgan Island, SC, and
weighed from 3.6 to 4.8 kg. Prior to use, all animals were determined to
HPIV3-seronegative by anHPIV3-speciﬁc HAI assay, with reciprocal HAI
titers b4. Two studies were performed. In the ﬁrst study (Figs. 1–3), we
infected four HPIV3-seronegative monkeys with two doses, 4 weeks
apart, of HPIV3by the combined IN and IT routewith 106 TCID50 per site,
as previously described (Bukreyev et al., 2004). Elevenmonths after the
second dose of HPIV3, two additional HPIV3-seronegative monkeys
were introduced into the study, and all six animalswere inoculatedwith
the HPIV3/EboGP vaccine by the combined IN and IT routes with 107
PFUper site as above. Fourweeks later, a second dose of the vaccinewas
administered identically to the ﬁrst dose. NS and TL were collected on
days 2, 4, 6, 8, and10after theﬁrst and the seconddoses of thevaccineas
previously described (Bukreyevet al., 2004). In the second study (Fig. 4),
we immunized two HPIV3-seronegative monkeys with a single dose of
HPIV3/EboGP and two additional HPIV3-seronegative monkeys with a
single dose of UV-inactivated HPIV3/EboGP. Immunizations were
performed by the combined IN and IT route with a dose 107 PFU or its
inactivated equivalent per site. NS and TL samples were collected as
above. The ﬁrst experiment was performed at Bioqual, Inc. (Rockville,
MD), and the second, at an NIAID facility (Poolesville, MD); both sites
are approved by the Association for Assessment and Accreditation of
Laboratory Care International. All procedures were performed in
accordance with protocols and guidelines approved by the NIAID
Animal Care and Use Committee.
Viruses and virological assays
HPIV3 and HPIV3/EboGP (Bukreyev et al., 2006) were propagated
in LLC-MK2 monkey kidney cells. The chimeric VSV-based virus
VSVΔG/ZEBOVGP (Garbutt et al., 2004), in which the VSV envelope
protein G had been replacedwith the GP of EBOV, was kindly provided
by Dr. Heinz Feldmann (Laboratory of Virology, Rocky Mountain
Laboratories, NIAID, NIH) and was propagated and titrated in Vero
cells. UV inactivation of HPIV3/EboGP was performed with a UV
Stratalinker 1800 (Stratagene, La Jolla, CA) using a UV dose of 128 mJ,
which was determined to be the minimal dose required for complete
inactivation of infectivity of the preparation. Titers of HPIV3/EboGP
were determined by plaque titration in LLC-MK2 cells visualized by
immunostaining, as previously described (Bukreyev et al., 2006).
Titers of HPIV3 were determined by limiting dilution in LLC-MK2 cells
and expressed as TCID50 per milliliter. For analysis of HPIV3/EboGP by
quantitative RT-PCR, total RNA was isolated from the cell culture
medium or from NS and TL specimens using the RNeasy mini kit
(Qiagen, Valencia, CA) according to manufacturer's recommenda-
tions. The RNA was subjected to reverse transcription with random
hexamer DNA primers and analyzed by quantitative PCR using
primers speciﬁc for the nucleoprotein gene of HPIV3 and the TaqMan
Gene Expression Assay (Applied Biosystems, Foster City, CA), as
previously described (Yang et al., 2008).
Serological assays
HPIV3-speciﬁc serum antibody responses were determined by HAI
assay in which serum dilutions were tested for the ability to block
agglutination of guinea pig erythrocytes by HPIV3, as previouslydescribed (van Wyke Coelingh et al., 1985). EBOV-speciﬁc antibody
responses were determined by ELISA, in which puriﬁed gamma-
irradiated EBOVwas used as an antigen, as previously described (Yang
et al., 2008). To quantify EBOV-neutralizing titers, we tested the
ability of the sera to neutralize VSVΔG/ZEBOVGP(Garbutt et al.,
2004). Serial dilutions of heat-inactivated monkey sera prepared in
Opti-Pro medium (Invitrogen, Carlsbad, CA) were mixed with an
equal volume of the virus. The virus dilutions were prepared in tissue
culture medium in the absence or presence of guinea pig complement
(Lonza Inc., Allendale, NJ) such that the ﬁnal concentration in the
neutralization mixtures was 1 TCID50 per microliter and 5% (v/v) of
complement. The serum/virus mixtures were incubated at 37 °C for
1 h, and 50 μl of each sample (equivalent to 50 TCID50 of input virus)
was added to conﬂuent monolayers of Vero cells in replicates of 4.
Wells were scored for virus replication by visual determination of
cytopathic effects (CPE) at 48 and 72 h post-infection. The serum-
neutralizing titer is reported as the highest serum dilution that results
in complete virus neutralization in 50% of the wells, as calculated
using the method of Reed and Muench (1938).
Statistics calculations
Statistical signiﬁcances were calculated by Student's T-test.
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